Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to CTEPH: Chronic thromboembolic pulmonary hypertension
CTEPHChronic Thromboembolic Pulmonary Hypertension
References in periodicals archive ?
Additional education on the preferred diagnostic test to identify CTEPH is needed.
Improved haemodynamics directly following inhalation of iloprost in patients with CTEPH has been previously shown, suggesting a significant reversible component of vasoconstriction in the pathophysiology of the disease (3).
The analysis of the CHEST-2 data cut-off showed that, at two years, mean exercise capacity of CTEPH patients as measured by the 6MWD had increased by 50m compared to CHEST-1 trial baseline.
Adempas (riociguat) tablets are indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class.
The availability of riociguat is a significant step forward: It means that patients with CTEPH for the first time have an option if pulmonary endarterectomy (PEA), a highly specialized surgical procedure, is not an option for them or when the disease persists after surgery.
com and take a quiz about the CTEPH symptoms, diagnosis, and treatment options, including the potentially curative surgery, pulmonary thromboendartorectomy.
The consistency and robustness of the positive results from the clinical trial programs CHEST and PATENT are substantial: Riociguat has demonstrated significant and sustained clinical efficacy and safety in treatment-naive PAH patients and patients pre-treated with endothelin-receptor antagonists (ERAs) or prostanoid monotherapy, as well as in patients with inoperable CTEPH or persistent or recurrent CTEPH after surgery.
Canada and Switzerland for the CTEPH indication and is under review in the EU.
com, answer four simple questions about CTEPH and upload the photo.
Riociguat achieves meaningful clinical improvements, which is a much needed step forward for patients whose CTEPH is inoperable or whose disease is persistent or recurrent.
com - is designed to increase CTEPH disease awareness among healthcare professionals (HCPs) and educate them on proper CTEPH diagnosis and surgical treatment.
Bayer HealthCare announced today that the United States Food and Drug Administration (FDA) has approved AdempasA (riociguat) tablets for use in two forms of pulmonary hypertension, a group of life-threatening and progressive diseases: The treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and the treatment of adults with pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening.